Sherry Korczynski Takes Charge as Chief Commercial Officer of Aquestive

Author: Owen Jenkins Updated: 07-22-2025 07:19 AM

Sherry Korczynski's Promotion at Aquestive Therapeutics

Recently, Aquestive Therapeutics, Inc. (NASDAQ: AQST) made headlines with the promotion of Sherry Korczynski to Chief Commercial Officer from her previous role as Senior Vice President of Sales and Marketing. This change is particularly exciting as the company gears up for its pivotal product, Anaphylm, which aims to revolutionize the way epinephrine is delivered to patients.

The Vision for Anaphylm

Sherry Korczynski's impressive record in the allergy market makes her the perfect fit for her new position. Daniel Barber, President and CEO of Aquestive, expressed confidence in her ability to lead the company's global commercial strategy. Anaphylm has the potential to be groundbreaking as it offers a device-free, orally delivered option for epinephrine, designed to help those at risk of anaphylaxis.

A Career Marked by Accomplishments

Korczynski has built a solid reputation over her more than twenty years in the pharmaceutical industry. Her journey began with significant roles in various prominent firms such as ANI Pharmaceuticals, Eagle Pharmaceuticals, and Mylan, where she oversaw the marketing of the EpiPen. With her educational background, including a B.S. in Marketing from The Pennsylvania State University and an M.B.A. from West Virginia University, she brings a wealth of knowledge and experience to her role at Aquestive.

About Anaphylm: A Groundbreaking Product

Anaphylm, which is a sublingual film containing epinephrine, could redefine how individuals react to anaphylactic emergencies. The film's compact design allows it to be easily carried, weighing less than an ounce and being smaller than a credit card. Importantly, it doesn’t require water for administration, making it practical for emergency situations.

Aquestive Therapeutics: Innovating Patient Care

Aquestive Therapeutics continues to focus on improving patient lives through innovative delivery methods. By working on orally administered products, the company aims to offer alternatives that surpass traditional, more invasive treatments. Currently, they have four commercialized products already making an impact in the market, leveraging their unique technologies such as PharmFilm®.

Looking Forward

Korczynski’s enthusiasm reflects the importance of this new product launch. She stated, “I am honored to take on this role at such a pivotal time for Aquestive.” This sentiment captures the excitement surrounding Anaphylm's upcoming release and the significant market potential it holds.

Frequently Asked Questions

What is Sherry Korczynski’s new role at Aquestive Therapeutics?

Sherry Korczynski has been promoted to Chief Commercial Officer, guiding the global commercial strategy for Anaphylm.

What is Anaphylm?

Anaphylm is a sublingual film containing epinephrine, designed to be administered without water, making it convenient for those with anaphylaxis.

What previous experience does Korczynski bring to her new role?

Korczynski has over two decades of experience in commercial leadership, notably with EpiPen marketing during her tenure at Mylan.

How is Aquestive Therapeutics impacting patient care?

Aquestive Therapeutics is developing innovative drug delivery technologies to enhance patient outcomes and provide alternatives to standard treatments.

What educational background supports Korczynski’s leadership?

Korczynski holds a B.S. in Marketing from The Pennsylvania State University and an M.B.A. from West Virginia University.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.